1.
Terai H, Tan L, Beauchamp EM, et al. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chem Biol. 2015;10(12):2687-96. doi:10.1021/acschembio.5b00655.
1.
Lozovsky ER, Chookajorn T, Brown KM, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A. 2009;106(29):12025-30. doi:10.1073/pnas.0905922106.
1.
Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015;528(7580):84-7. doi:10.1038/nature15736.
1.
Ogbunugafor B, Wylie S, Diakite I, Weinreich DM, Hartl DL. Adaptive Landscape by Environment Interactions Dictate Evolutionary Dynamics in Models of Drug Resistance. PLoS Comput Biol. 2016;12(1):e1004710. doi:10.1371/journal.pcbi.1004710.
1.
Krueger AS, Munck C, Dantas G, et al. Simulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis. PLoS One. 2016;11(1):e0147651. doi:10.1371/journal.pone.0147651.
1.
Geng B, Basarab G, Comita-Prevoir J, et al. Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): pyridodiazepine amines. Bioorg Med Chem Lett. 2009;19(3):930-6. doi:10.1016/j.bmcl.2008.11.113.
1.
Tang W, Luo T, Greenberg EF, Bradner JE, Schreiber SL. Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett. 2011;21(9):2601-5. doi:10.1016/j.bmcl.2011.01.134.